PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant

2013-10-31
(Press-News.org) Contact information: Dwight Angell
dwight.angell@hfhs.org
313-850-3471
Henry Ford Health System
Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant DETROIT – New drug therapies offer promise to some hepatitis C sufferers whose transplanted livers are threated by a recurrence of the disease, including some patients who have had no treatment options.

The encouraging findings are contained in two new studies by a collaboration of researchers across the U.S. – as well as in Spain and New Zealand – including Dilip Moonka, M.D., medical director of Liver Transplant at Henry Ford Hospital.

Both studies are being presented at the annual meeting of the American Association for the Study of Liver Disease being held in Washington, DC, Nov. 1-5.

Both studies focused on the experimental anti-viral drug sofosbuvir, a direct-acting oral medication that may take the place of injectable interferon, which causes severe side effects in some patients.

The U.S. Food and Drug Administration is expected to decide in early December whether to approve its use for treating hepatitis C. Last week, the Antiviral Drugs Advisory Committee of the FDA voted unanimously in support of approval for sofosbuvir-based therapies for the treatment of chronic hepatitis C.

Chronic hepatitis C, which afflicts an estimated 3 million people in the U.S. alone, is a blood-borne viral disease that leads to scarring and deterioration of the liver. It is particularly insidious because patients usually don't develop symptoms until the scarring – or cirrhosis – is well underway.

Sofosbuvir, which belongs to a class of drugs known as nucleotide analogue polymerase inhibitors, acts at the molecular level by interfering with the RNA of the hepatitis C virus.

In the first newly released study, researchers tested it as an alternative to interferon, a naturally occurring protein that plays a role in fighting viral infections, but commonly produces a range of serious side effects.

The researchers used it in combination with ribavirin, which also inhibits the hepatitis C virus by interfering with its RNA to stem the replication of the virus and slow the progression of the disease. They sought to test the drug combination's effectiveness in preventing recurrence of hepatitis C in liver transplant recipients.

A total of 61 chronic hepatitis C patients with liver cancer were enrolled in the study and given both sofosbuvir and ribavirin daily for up to 48 weeks before liver transplant. All of the patients had well-compensated cirrhosis, meaning their bodies were still functioning without too much trouble despite liver scarring. The researchers found that the new drug combination was both safe and effective in such patients and prevented post-transplant recurrence of the hepatitis C virus in more than 60 percent of them.

In the second newly released study, researchers focused on liver transplant recipients whose severe hepatitis C recurred after surgery and who either couldn't tolerate or didn't respond to approved antiviral therapies – leaving them with no other effective treatment options.

In such cases, experimental drugs can sometimes be tested under "compassionate use" protocols.

The researchers reported that as of April, 115 patients were approved for compassionate use of sofosbuvir combined with ribavirin and/or the anti-viral drug peginterferon. At the time of their report, 63 had started treatment.

After several weeks of treatment and study, the researchers concluded that patients with severe recurrence of hepatitis C after receiving transplanted livers were able to tolerate the drug regimen, which produced strong anti-viral effects.

### They reported "notable clinical improvements and/or disease stabilization in a majority of the patients."

Funding Source: Gilead Pharmaceuticals


ELSE PRESS RELEASES FROM THIS DATE:

Scientists discover why newborns get sick so often

2013-10-31
Scientists discover why newborns get sick so often New research published in the Journal of Leukocyte Biology suggests that newborns lack the toll-like receptor 3 (TLR3) which recognizes different viruses and mediates immune response ...

Studies: Current hepatitis C treatments can't be used by more than half of patients; others lose opportunity for treatment

2013-10-31
Studies: Current hepatitis C treatments can't be used by more than half of patients; others lose opportunity for treatment DETROIT – More than half of chronic hepatitis C patients studied in a new research project led by Henry Ford Hospital were not treated ...

HIV antibody infusions show promise for treating SHIV-infected monkeys

2013-10-31
HIV antibody infusions show promise for treating SHIV-infected monkeys NIH-supported scientists advocate trying similar strategy in people WHAT: Two teams are reporting results from experiments in which they infused powerful ...

Study: Fast, painless alternative to liver biopsies for hepatitis patients proves accurate and reliable

2013-10-31
Study: Fast, painless alternative to liver biopsies for hepatitis patients proves accurate and reliable DETROIT – A non-invasive alternative to liver biopsy, now the standard method of diagnosing cirrhosis in hepatitis patients, proved very reliable in a national ...

Gaming technology unravels 1 of the most complex entities in nature

2013-10-31
Gaming technology unravels 1 of the most complex entities in nature Computational research unveils secrets in the human carbohydrate bar-code BBSRC-funded researchers at the University of Manchester's Institute of Biotechnology have ...

The secret's in the (robotic) stroke

2013-10-31
The secret's in the (robotic) stroke NYU-Poly researchers tease out cues that impact schooling fish behavior Brooklyn, New York— Recent studies from two research teams at the Polytechnic Institute of New York University (NYU-Poly) demonstrate ...

Increasing rate of knee replacements linked to obesity among young, researchers say

2013-10-31
Increasing rate of knee replacements linked to obesity among young, researchers say New data show younger adults have same or greater impairment than older patients BOSTON – Contrary to popular myth, it is not the aging Baby Boomer or weekend ...

Newly identified proteins make promising targets for blocking graft-vs.-host disease

2013-10-31
Newly identified proteins make promising targets for blocking graft-vs.-host disease Finding could help improve outcomes from bone marrow transplants ANN ARBOR, Mich. — Researchers from the University of Michigan Comprehensive Cancer Center have ...

Biochemists find incomplete protein digestion is a useful thing for some bacteria

2013-10-31
Biochemists find incomplete protein digestion is a useful thing for some bacteria To the authors' surprise, 1 specialized replication factor was partially digested or trimmed, physically cut into shorter fragments, by an energy-dependent protease ...

Long-term use of prescription-based painkillers increases the risk of depression, SLU researcher finds

2013-10-31
Long-term use of prescription-based painkillers increases the risk of depression, SLU researcher finds ST. LOUIS – Opioid analgesics, or prescription-based narcotic pain killers, have long been known to reduce pain, but reports of adverse effects and addiction continue ...

LAST 30 PRESS RELEASES:

Attitudes, not income, drive energy savings at home

The playbook for perfect polaritons

‘Disease in a dish’ study of progressive MS finds critical role for unusual type of brain cell

Solar-powered method lights the way to a ‘de-fossilized’ chemical industry

Screen time linked to lower academic achievement among Ontario elementary students

One-year outcomes after traumatic brain injury and early extracranial surgery in the TRACK-TBI Study

Enduring outcomes of COVID-19 work absences on the US labor market

Affirmative action repeal and racial and ethnic diversity in us medical school admissions

Cancer progression illuminated by new multi-omics tool

Screen time and standardized academic achievement tests in elementary school

GLP-1RA order fills and out-of-pocket costs by race, ethnicity, and indication

Study finds HEPA purifiers alone may not be enough to reduce viral exposure in schools

UVA Health developing way to ID people at risk of dangerous lung scarring even before symptoms appear

How can we know when curing cancer causes myocarditis?

Male infertility in Indian men linked to lifestyle choices and hormonal imbalances

An acoustofluidic device for sample preparation and detection of small extracellular vesicles

The advent of nanotechnology has ushered in a transformative era for oncology, offering unprecedented capabilities for targeted drug delivery and controlled release. This paradigm shift enhances thera

A prototype LED as thin as wallpaper — that glows like the sun

Transnational electoral participation of undocumented Mexican immigrants in the US

A new method to build more energy-efficient memory devices for a sustainable data future

Freely levitating rotor spins out ultraprecise sensors for classical and quantum physics

‘Chinese lantern’ structure shifts into more than a dozen shapes for various applications

Towards light-controlled electronic components

Tiny architects, titanic climate impact: scientists call for October 10 to become International Coccolithophore Day

Stress sensitivity makes suicidal thoughts more extreme and persistent among the university population

Lessons from Ascension’s shark troubles could help boost conservation

Fire provides long-lasting benefits to bird populations in Sierra Nevada National Parks

Menstrual cycle affects women’s reaction time but not as much as being active

Housing associations more effective than government in supporting unemployed in deprived areas

Biochar helps composting go greener by cutting greenhouse gas emissions

[Press-News.org] Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant